Free Trial
NASDAQ:THTX

Theratechnologies (THTX) Stock Price, News & Analysis

Theratechnologies logo
$2.36 +0.01 (+0.43%)
As of 04:00 PM Eastern

About Theratechnologies Stock (NASDAQ:THTX)

Key Stats

Today's Range
$2.30
$2.39
50-Day Range
$2.34
$2.92
52-Week Range
$1.12
$3.13
Volume
67,063 shs
Average Volume
818,356 shs
Market Capitalization
$108.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Receive THTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter.

THTX Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
Theratechnologies to further evaluate potential sale of the company
Theratechnologies Provides Update on Sale Process
See More Headlines

THTX Stock Analysis - Frequently Asked Questions

Theratechnologies' stock was trading at $1.81 at the beginning of 2025. Since then, THTX shares have increased by 30.4% and is now trading at $2.36.
View the best growth stocks for 2025 here
.

Theratechnologies Inc. (NASDAQ:THTX) released its quarterly earnings results on Thursday, October, 10th. The company reported $0.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.03 by $0.03. The business had revenue of $22.60 million for the quarter.
Read the conference call transcript
.

Shares of Theratechnologies reverse split on Monday, July 31st 2023.The 1-4 reverse split was announced on Monday, July 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

The following companies are subsidiaries of Theratechnologies: Katana, Pharma-G Inc., Theratechnologies Europe Inc., Theratechnologies Europe Limited, Theratechnologies Intercontinental Inc., and Theratechnologies U.S. Inc.

Shares of THTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Theratechnologies investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), CymaBay Therapeutics (CBAY), Novo Nordisk A/S (NVO), Adobe (ADBE) and Celestica (CLS).

Company Calendar

Last Earnings
10/10/2024
Today
6/30/2025
Next Earnings (Estimated)
7/09/2025
Fiscal Year End
11/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:THTX
Employees
140
Year Founded
1993

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
232.00
P/E Growth
N/A
Net Income
-$8.31 million
Pretax Margin
-7.34%

Debt

Sales & Book Value

Annual Sales
$85.87 million
Price / Cash Flow
N/A
Book Value
($0.55) per share
Price / Book
-4.22

Miscellaneous

Free Float
N/A
Market Cap
$106.67 million
Optionable
Optionable
Beta
0.60

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:THTX) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners